Triple-Drug attack aims to wipe out blood cancer cells

NCT ID NCT03824483

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial is testing a combination of three drugs—zanubrutinib, obinutuzumab, and venetoclax—in people with previously untreated chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL). The goal is to see if the combo can make the cancer undetectable in the bone marrow and blood. The study plans to enroll 230 participants and is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanubrutinib, obinutuzumab, and venetoclax
What this could lead to: If successful, this combination could offer a powerful, chemotherapy-free option that drives CLL, SLL, or MCL into deep remission with no detectable cancer cells.
What could go wrong: This is a Phase 2 trial, so it's still early. The three-drug regimen may cause significant side effects, and not all patients may achieve undetectable disease. Long-term outcomes are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) SMALL LYMPHOCYTIC LEUKEMIA (SLL)

Contacts and locations

Locations

Massachusetts General Hospital (Data Collection and Specimen Analysis)
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Commack
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau
RECRUITING

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester
RECRUITING

Harrison, New York, 10604, United States
Memorial Sloan Kettering at Basking Ridge
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Northwestern University
RECRUITING

Evanston, Illinois, 60208, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.